Although GSK-3β depletion didn’t affect p53-null colon cancer cell lines, it has been demonstrated that GSK-3β silencing sensitized chemoresistant p53-null colon cancer cells to antitumor effects of DNA–damaging drugs26. This evidence concerns the gene TP53 and colonic neoplasm.